Medistim Logo

Medistim ist ein norwegischer Hersteller und Anbieter von Medizintechnikprodukten. Der Schwerpunkt des Unternehmens liegt auf intraoperativen Qualitätskontrollanwendungen für die Herz-, Transplantations- und Gefäßchirurgie. Innerhalb dieser Nische nimmt Medistim derzeit annähernd eine Monopolstellung ein. Die Kombination aus TTFM-Technologie (transit time flow measurement) und Ultraschallbildgebung machen deren Produkte VeriQ-C sowie MiraQ einzigartig und werden daher auch von den führenden Guidelines für die Anwendung bei Bypass-Operationen empfohlen.   

Unsere Aktienanalysen

News zu Medistim

  • Webinar: Second Quarter and Half-yearly Financial Report
    von Benedicte Meydel am 30/06/2020 um 07:54

    Sign up for the upcoming financial report presentation. You’re invited to join this presentation on Friday 14 August at 8 AM CEST. CEO Kari E. Krogstad and CFO Thomas Jakobsen will present the second quarter and half-year report, and 1 hour is set aside including a Q&A session.  Sign up here >> We look forward to The post Webinar: Second Quarter and Half-yearly Financial Report appeared first on Medistim.

  • Protocol from the General Meeting 2020
    von amanda.abrahamson am 25/06/2020 um 15:15

    Minutes from the General Meeting in Medistim ASA 2020 Minutes from the General Meeting 2020 The post Protocol from the General Meeting 2020 appeared first on Medistim.

  • Benefits of Medistim technology in Carotid Endarterectomy published in EJVES
    von Benedicte Meydel am 08/05/2020 um 08:03

    The CIDAC study is a prospective trial comparing high-frequency ultrasound (HFUS, named IDUS in the study) and angiography in 150 patients as intraoperative completion control after removal of plaque in a neck artery, a procedure called carotid endarterectomy (CEA).  The aim of a CEA procedure is to remove plaque that might become a source of The post Benefits of Medistim technology in Carotid Endarterectomy published in EJVES appeared first on Medistim.

  • Results for the First Quarter 2020
    von Benedicte Meydel am 29/04/2020 um 08:07

    Sales for the quarter ended at a record high MNOK 103.1 (MNOK 88.7), a 16.2% increase.This was driven by strong growth in capital sales of systems in Japan after regulatory approval of MiraQ™. Read the full report and presentation below. 1.quarter 2020 report Medistim Q1 2020 presentation   The post Results for the First Quarter 2020 appeared first on Medistim.

  • Company Presentation April 2020
    von Benedicte Meydel am 01/04/2020 um 09:38

    The post Company Presentation April 2020 appeared first on Medistim.